Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Alsaadi et al. [4] 2008 RS 2/9 CD NR 24 NR
66.7% (6/9)b 		NR NR NR NR
Cauble [35] 2011 CR 1/10 CD 1/0 5 100% (1/1)
100% (10/10)c 		NR NR NR NR
Alsaadi et al. [67] 2008 RS NR/12 CD NR Up to prosthetic loading NR
91.7% (11/12)c 		NR NR NR NR
van Steenberghe et al. [74] 2002 RS 3/13 CD NR Up to prosthetic loading 33.3% (1/3)
76.9% (10/13)c 		NR NR NR NR
Overall
CD - RS: 3
CR: 1 		6/44 - Ratio: 1/0 Mean: 17.7 50% (2/4)
84.1% (37/44)
Of these: 57.1% (4/7) early loss 		NR NR NR NR
CD
+concomitant ADs 		- Irr. None - Irr. Irr. Irr. Irr. Irr. Irr. Irr.

a = weighted mean or median; b = early loss NR; c = late loss NR.
ADs = autoimmune diseases; CR = case report; Irr. = irrelevant; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; RS = retrospective study.